Vanguard Total International Bond ETF (BNDX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
- PR Newswire•5 days ago
BiondVax Pharmaceuticals Ltd. (BVXV) announced today that the last participant in a European Phase 2b clinical trial of M-001, its universal flu vaccine candidate, has completed their final visit. Conducted in collaboration with the EU-sponsored UNISEC consortium, the trial is designed to evaluate the safety and immunogenicity of M-001 when used ahead of a pandemic influenza vaccine. In 2009, following the official World Health Organization (WHO) declaration of a H1N1 swine flu pandemic, it took about 6 months until vaccines against the new strain could be administered.
- PR Newswire•19 days ago
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, is pleased to announce the appointment of Professor Shai Ashkenazi to its Scientific Advisory Board (SAB). Ashkenazi is a clinical and regulatory vaccine expert, with significant contributions to flu and other infectious disease vaccine research and development.
- Sam Ro•22 days ago
On September 21, the Fed is gonna do it. The US economy is adding jobs at a rate that’s “just enough” for most members of the Fed’s Federal Open Market Committee (FOMC) to vote for a rate hike this month, Goldman Sachs’ Jan Hatzius argued. During the global financial crisis, the Federal Reserve loosened monetary policy and lowered interest rates aggressively in its effort to stimulate the tumbling economy.